Table 1.
Characteristics of the analyzed population (n = 175).
| Overall | |
|---|---|
| Age, year | 69 (63/76) |
| BMI, kg/m2 | 24.2 (22.3/26.2) |
| Smoking | 77 (44%) |
| Alcohol | 72 (41%) |
| Prostate volume, cc | 62 (46/87) |
| Total PSA, ng/ml | 3.37 (1.49/7.42) |
| Waist circumference ≥90 cm | 109 (62%) |
| HDL <1.03 mmol/L or on drug treatment to reduced HDL-cholesterol | 52 (30%) |
| Triglyceride ≥1.7 mmol/L or on drug treatment for elevated triglycerides | 31 (18%) |
| Fasting glucose ≥5.6 mmol/L or on drug treatment for elevated glucose | 58 (33%) |
| SBP ≥130 mmHg and/or DBP ≥85 mmHg or on antihypertensionsive drug treatment in a patient with history of hypertension | 127 (73%) |
| MetS | 63 (36%) |
| Preoperative IPSS | |
| Total | 21 (17/27) |
| vIPSS | 12 (10/16) |
| sIPSS | 9 (7/12) |
| Nocturia | 4 (3/5) |
| IPSS 3 mo | |
| Total | 5 (3/7) |
| vIPSS | 1 (0/3) |
| sIPSS | 3 (2/5) |
| Nocturia | 2 (1/3) |
| Nocturia improvement | 80 (46%) |
BMI, body mass index; PSA, prostate-specific antigen; HDL, high-density lipoprotein; SBP, systolic blood pressure; DBP, diastolic blood pressure; MetS, metabolic syndrome; IPSS, International Prostate Symptom Score; vIPSS, voiding International Prostate Symptom Score; sIPSS, storage International Prostate Symptom Score.